These products can cause harm through what they lack and what they secretly contain
À medida que a semaglutida — o princípio ativo do Ozempic — se tornou um dos medicamentos mais desejados do mundo, tanto pelo controle do diabetes quanto pela perda de peso, ela também se tornou alvo de falsificadores. A Organização Mundial da Saúde emitiu um alerta global sobre a circulação crescente de versões falsificadas do produto em múltiplos continentes desde 2022, documentando lotes fraudulentos no Brasil, no Reino Unido, na Irlanda do Norte e nos Estados Unidos. O perigo reside não apenas na ineficácia dessas cópias, mas no que elas podem conter ou omitir — colocando em risco justamente aqueles que mais dependem de tratamentos confiáveis.
- Desde 2022, o sistema global de vigilância da OMS registra aumento contínuo de relatos de semaglutida falsificada em todas as regiões do mundo.
- Lotes falsos identificados no Brasil, Reino Unido, Irlanda do Norte e EUA revelam um problema disseminado, não episódios isolados.
- O produto falsificado pode não conter o princípio ativo — deixando diabéticos sem controle glicêmico — ou esconder substâncias não declaradas com efeitos imprevisíveis.
- A explosão na demanda pelo efeito emagrecedor do Ozempic, amplificada por celebridades e redes sociais, criou incentivo econômico direto para criminosos inundarem o mercado com versões fraudulentas.
- A OMS orienta pacientes a comprar apenas com receita médica, evitar fontes online não verificadas e inspecionar embalagens e prazos de validade.
- Um canal de denúncias foi aberto pela organização para que pacientes e profissionais de saúde reportem suspeitas diretamente, alimentando o sistema de vigilância global.
A Organização Mundial da Saúde emitiu um alerta sobre a circulação de versões falsificadas de semaglutida — princípio ativo do Ozempic — em múltiplos continentes. O medicamento, prescrito para diabetes tipo 2, ganhou enorme procura nos últimos anos por seu efeito secundário de perda de peso significativa, tornando-se alvo atraente para falsificadores.
Desde 2022, o sistema de vigilância da OMS registra crescimento constante de relatos de produtos falsos. Três lotes específicos foram identificados no Brasil, no Reino Unido e na Irlanda do Norte em outubro de 2023, e versões adicionais foram descobertas nos Estados Unidos dois meses depois — um padrão que aponta para um problema amplo e sistemático.
O risco vai além da simples ineficácia. Um produto falsificado pode não conter nenhum princípio ativo, privando pacientes diabéticos do controle glicêmico de que dependem. Em outros casos, pode conter substâncias não declaradas, gerando complicações imprevisíveis. A OMS destacou que o perigo está tanto no que falta quanto no que está escondido.
A demanda crescente — impulsionada pela repercussão do efeito emagrecedor em redes sociais e pelo uso por celebridades — criou incentivo econômico direto para a produção e distribuição de falsificações, especialmente por canais online de difícil rastreamento.
A organização recomenda que pacientes adquiram o medicamento apenas com receita de profissional habilitado, evitem fontes não verificadas, inspecionem embalagens e datas de validade, e garantam o armazenamento correto sob refrigeração. Suspeitas de falsificação podem ser reportadas diretamente à OMS pelo e-mail [email protected], alimentando o monitoramento global do problema.
The World Health Organization has issued a fresh warning about counterfeit versions of semaglutida—the active ingredient in Ozempic—circulating across multiple continents. The injectable medication, prescribed for type 2 diabetes, has become widely sought after in recent years for its secondary effect: significant weight loss. That popularity has made it a target for counterfeiters.
Since 2022, the WHO's global surveillance system has tracked a steady rise in reports of fake semaglutida products appearing in every geographic region. The organization has documented three specific counterfeit batches of Ozempic identified in Brazil, the United Kingdom, and Northern Ireland in October 2023, with additional fake versions discovered in the United States two months later. The pattern suggests a coordinated or at least widespread problem, not isolated incidents.
The danger is not merely that these products don't work. A counterfeit semaglutida injection might contain no active ingredient at all, leaving a diabetic patient without the medication they need to control their blood sugar—a situation that can lead to serious, even life-threatening complications. In other cases, the fake device might contain an undeclared active substance, creating an unpredictable range of health risks that neither the patient nor their doctor anticipated. The WHO emphasized that these counterfeit products can cause harm through both what they lack and what they secretly contain.
The surge in counterfeits tracks directly with surging demand. As awareness of semaglutida's weight-loss effects has spread—amplified by celebrity use and social media—more people have sought the medication, whether for diabetes management or weight reduction. That demand has created economic incentive for criminals to manufacture and distribute fake versions, often through online channels where verification is difficult or impossible.
The WHO has issued specific guidance for patients trying to protect themselves. Buy only with a prescription from a licensed healthcare provider. Avoid unknown or unverified sources, particularly online retailers operating outside regulated channels. When you receive the medication, inspect the packaging carefully and check the expiration date. For injectable semaglutida, proper storage in a refrigerator is essential—and counterfeiters may not have maintained correct cold-chain conditions during manufacturing and distribution.
The organization has also opened a reporting channel: patients or healthcare providers who suspect they have encountered counterfeit semaglutida can notify the WHO directly at [email protected]. These reports feed into the global surveillance system, helping the organization track where fakes are appearing and how the problem is evolving.
What makes this warning particularly urgent is the vulnerability of the people most likely to use these medications. Diabetic patients depend on reliable access to their treatments; missing doses or using ineffective medication can trigger dangerous blood sugar swings. Meanwhile, people seeking weight-loss medication through unofficial channels are often doing so precisely because they lack access to legitimate prescriptions—making them especially susceptible to counterfeit products. The WHO's alert is a recognition that as demand for semaglutida continues to climb, the counterfeit market will likely grow with it.
Citas Notables
Fake products may lack necessary active ingredients, leading to uncontrolled blood glucose and weight complications, or contain undeclared active substances creating unpredictable health risks— WHO
La Conversación del Hearth Otra perspectiva de la historia
Why is Ozempic specifically becoming a target for counterfeiters now, when it's been around for years?
The timing matters. The drug was approved for diabetes long ago, but it only became a mass-market phenomenon when people realized it caused significant weight loss. That created a huge new population of people wanting it—not just diabetics managing a chronic condition, but people seeking cosmetic weight loss. Suddenly the addressable market exploded, and with it, the profit motive for criminals.
What's the actual health risk if someone injects a completely fake version with no active ingredient?
For a diabetic, it's serious. Your blood sugar goes uncontrolled. You could develop diabetic ketoacidosis, which is a medical emergency. For someone using it for weight loss, the immediate risk is lower, but they're still out money and time. The real danger is the unknown—you don't know what you're injecting.
The WHO mentions "undeclared active substances." What does that mean in practice?
It means the counterfeit might contain some other drug entirely—maybe a different diabetes medication, maybe something that was never meant for human injection. You're essentially playing Russian roulette with your body. Your doctor prescribed semaglutida at a specific dose for a specific reason. An unknown substance could interact with your other medications or cause allergic reactions.
Why is buying online so risky compared to a pharmacy?
A legitimate pharmacy is regulated, inspected, has supply chain documentation. An online seller operating outside that system has no accountability. They can source from anywhere, store the product improperly, and disappear if something goes wrong. There's no recourse.
If someone suspects they have a fake, what actually happens when they contact the WHO?
Their report goes into the global surveillance database. If enough reports cluster around the same batch number or seller, it helps the WHO and national health authorities identify where counterfeits are being distributed and potentially shut down the source. It's not immediate help for that individual, but it's how the system learns and responds.